Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will present new clinical biopsy data from the ongoing Phase 1 ELIMINATE-B trial during a late-breaking poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The ELIMINATE-B trial is evaluating PBGEN.